secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000882095-24-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance
-----------------------------------------------------------

- GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.
- Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).
- Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.
- Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.
- Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/0000882095-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000025/gild-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000882095-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer